6 days Ago By ABMN Staff
Mariner LLC raised its stake in shares of Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX – Free Report ) by 32.9% during the fourth quarter, Holdings Channel.
com reports. The institutional investor owned 111,063 shares of the company’s stock after buying an additional 27,499 shares during the period. Mariner LLC’s holdings in Recursion Pharmaceuticals were worth $751,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 40.
1% during the fourth quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company’s stock worth $229,908,000 after purchasing an additional 9,737,196 shares during the last quarter.
Geode Capital Management LLC boosted its holdings in shares of Recursion Pharmaceuticals by 12.1% during the fourth quarter. Geode Capital Management LLC now owns 6,087,149 shares of the company’s stock worth $41,160,000 after purchasing an additional 655,238 shares during the last quarter.
Norges Bank acquired a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth $23,429,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 17.
2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,274,003 shares of the company’s stock worth $15,372,000 after purchasing an additional 333,323 shares during the last quarter.
Finally, JPMorgan Chase & Co. increased its stake in Recursion Pharmaceuticals by 6.1% during the third quarter.
JPMorgan Chase & Co. now owns 1,176,191 shares of the company’s stock worth $7,751,000 after acquiring an additional 67,464 shares during the last quarter. Institutional investors and hedge funds own 89.
06% of the company’s stock. Wall Street Analyst Weigh In A number of analysts have recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $11.
00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday, April 8th. Leerink Partners reduced their target price on Recursion Pharmaceuticals from $7.00 to $6.
00 and set a “market perform” rating for the company in a research note on Friday, February 28th. KeyCorp reduced their target price on Recursion Pharmaceuticals from $12.00 to $10.
00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Morgan Stanley dropped their price target on Recursion Pharmaceuticals from $10.00 to $8.
00 and set an “equal weight” rating on the stock in a research report on Thursday, April 10th. Finally, Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock.
According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $8.20.
Recursion Pharmaceuticals Price Performance Shares of NASDAQ RXRX opened at $5.84 on Tuesday. Recursion Pharmaceuticals, Inc.
has a 1-year low of $3.79 and a 1-year high of $12.36.
The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.
35. The business’s fifty day moving average price is $6.11 and its two-hundred day moving average price is $6.
78. The firm has a market capitalization of $2.35 billion, a PE ratio of -3.
82 and a beta of 1.00. Recursion Pharmaceuticals ( NASDAQ:RXRX – Get Free Report ) last issued its earnings results on Friday, February 28th.
The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.
17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.
52%. The company had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.
04 million. During the same period in the prior year, the business earned ($0.42) earnings per share.
Recursion Pharmaceuticals’s quarterly revenue was down 57.8% on a year-over-year basis. On average, research analysts expect that Recursion Pharmaceuticals, Inc.
will post -1.57 EPS for the current year. Recursion Pharmaceuticals Profile ( Free Report ) Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Featured Stories Want to see what other hedge funds are holding RXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recursion Pharmaceuticals, Inc.
( NASDAQ:RXRX – Free Report ). Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
